Théa completes eyecare expansion with Akorn's branded ophthalmic products

Article

The purchase gives Théa ownership over seven products across the therapeutic space, including glaucoma and ocular surface disease.

Théa completes eyecare expansion with Akorn's branded ophthalmic products


Théa Pharma Inc has finished its acquisition of seven branded ophthalmic products from Akorn Operating Company LLC., the company announced Wednesday.

With this latest development, Théa now owns the following products:

  • Zioptan(tafluprost ophthalmic solution), a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • AcellFX (acellular amniotic membrane), which provides a protective environment or covering for repair to the ocular surface.
  • Betimol(timolol ophthalmic solution), indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
  • Cosopt (dorzolamide HCl and timolol maleate ophthalmic solution), indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to beta blockers.
  • Cosopt PF (dorzolamide HCl and timolol maleate ophthalmic solution), indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to beta blockers.
  • AzaSite (azithromycin ophthalmic solution), a macrolide antibiotic indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of certain microorganisms; and

Akten (lidocaine HCl ophthalmic gel), a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures.

Also included in the purchase is Akorn's nearly 50-person sales force, which Théa intends to expand with the anticipated launch and growth of additional products within the US.

“The closing of this transaction bolsters Théa’s mission to provide innovative treatments across a range of therapeutic areas, including glaucoma, dry eye, allergy, and inflammation,” said Théa President Jean-Frédéeric Chibret, in a statement.

Théa’s acquisition is part of the company’s larger commitment to develop cutting-edge products for the U.S. market in areas of unmet needs, according to the release.

Launch activities have also begun this month for its evidence-based line of iVIZIA OTC products for eyelid hygiene and dry eye, the company stated. Further, last month Théa its filed its first New Drug Application (NDA) from the FDA for a version of latanoprost.

Related: Théa to acquire 7 branded ophthalmic products from Akorn


Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.